These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 10928160

  • 21. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
    Lissoni P, Tisi E, Barni S, Ardizzoia A, Rovelli F, Rescaldani R, Ballabio D, Benenti C, Angeli M, Tancini G.
    Br J Cancer; 1992 Jul; 66(1):155-8. PubMed ID: 1322155
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.
    Lissoni P, Barni S, Fossati V, Ardizzoia A, Cazzaniga M, Tancini G, Frigerio F.
    Support Care Cancer; 1995 May; 3(3):194-7. PubMed ID: 7655780
    [Abstract] [Full Text] [Related]

  • 24. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
    Mantovani G, Macciò A, Mulas C, Massa E, Madeddu C, Mura L, Contu P, Versace R.
    Oncol Rep; 2002 May; 9(3):661-70. PubMed ID: 11956647
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
    Lissoni P, Barni S, Tancini G, Mainini E, Piglia F, Maestroni GJ, Lewinski A.
    Oncology; 1995 May; 52(2):163-6. PubMed ID: 7854778
    [Abstract] [Full Text] [Related]

  • 27. Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer.
    Lissoni P, Pittalis S, Rovelli F, Vigorè L, Roselli MG, Brivio F.
    J Biol Regul Homeost Agents; 1995 May; 9(2):63-6. PubMed ID: 9127635
    [Abstract] [Full Text] [Related]

  • 28. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
    Mantovani G, Macciò A, Madeddu C, Mulas C, Massa E, Astara G, Ferreli L, Mudu MC, Gramignano G, Murgia V, Lusso MR, Mocci M, Cardia A, Mura L.
    Oncol Rep; 2002 May; 9(4):887-96. PubMed ID: 12066227
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Melatonin as biological response modifier in cancer patients.
    Neri B, de Leonardis V, Gemelli MT, di Loro F, Mottola A, Ponchietti R, Raugei A, Cini G.
    Anticancer Res; 1998 May; 18(2B):1329-32. PubMed ID: 9615811
    [Abstract] [Full Text] [Related]

  • 33. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
    Lissoni P, Mandalà M, Brivio F.
    Eur Urol; 2000 Jul; 38(1):115-8. PubMed ID: 10859453
    [Abstract] [Full Text] [Related]

  • 34. Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer.
    Recchia F, De Filippis S, Rosselli M, Saggio G, Cesta A, Fumagalli L, Rea S.
    Clin Cancer Res; 2001 May; 7(5):1251-7. PubMed ID: 11350891
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Immunomodulatory properties of a pineal indole hormone other than melatonin, the 5-methoxytryptophol.
    Lissoni P, Pittalis S, Rovelli F, Zecchini S, Casati M, Tremolada M, Pelizzoni F.
    J Biol Regul Homeost Agents; 1996 May; 10(1):27-30. PubMed ID: 9049779
    [Abstract] [Full Text] [Related]

  • 37. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Ridolfi L, Fiorentini G, Guida M, Michiara M, Freschi A, Aitini E, Ballardini M, Bichisao E, Ridolfi R, Italian Melanoma Intergroup.
    Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.